Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice
Arvind Thakkar,1 Sushma Chenreddy,1 Astrid Thio,1 Wael Khamas,2 Jeffrey Wang,1 Sunil Prabhu1 1Department of Pharmaceutical Sciences, College of Pharmacy, 2College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA, USA Abstract: Our previous studies have established the effi...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/94ab8fee00204a259e57bfa9e5b78417 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:94ab8fee00204a259e57bfa9e5b78417 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:94ab8fee00204a259e57bfa9e5b784172021-12-02T03:58:30ZPreclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice1178-2013https://doaj.org/article/94ab8fee00204a259e57bfa9e5b784172016-07-01T00:00:00Zhttps://www.dovepress.com/preclinical--systemic-toxicity-evaluation-of-chitosan-solidndashlipid--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Arvind Thakkar,1 Sushma Chenreddy,1 Astrid Thio,1 Wael Khamas,2 Jeffrey Wang,1 Sunil Prabhu1 1Department of Pharmaceutical Sciences, College of Pharmacy, 2College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA, USA Abstract: Our previous studies have established the efficacy of chemopreventive regimens of aspirin and curcumin (CUR) encapsulated within solid lipid nanoparticles (SLNs) in combination with free sulforaphane (ACS combination) to prevent or delay the initiation and progression of pancreatic cancer, classified as one of the deadliest diseases with very low chances of survival upon diagnosis. Although toxicity of individual drugs and SLN has been studied previously, there are no studies in current literature that evaluate the potential toxicity of a combined regimen of ACS, especially when encapsulated within chitosan-SLNs (c-SLNs). Hence, objective of the current study was to investigate the potential toxic effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), subacute (28 days), and subchronic (90 days) administrations by oral gavage in BALB/c mice. Mice were administered the following regimens: saline, blank c-SLN, low-dose ACS c-SLN (2+4.5+0.16 mg/kg), medium-dose ACS c-SLN (20+45+1.6 mg/kg), and high-dose ACS c-SLN (60+135+4.8 mg/kg). The potential toxicity was evaluated based on animal survival, body weight, hematology, blood chemistry, and organ histopathology. During 3-day, 28-day, and 90-day study periods, no animal deaths were observed. Treatment with ACS c-SLNs did not cause alteration in complete blood counts and blood chemistry data. Histopathological examination of various organ sections (pancreas, heart, liver, kidney, and brain) appeared normal. Based on the results of this study, no signs of toxicity in acute, subacute, and subchronic studies following oral administration of ACS c-SLNs were found indicating that the oral dosing regimens were safe at the levels tested for long-term administration to prevent the onset of pancreatic cancer. Keywords: pancreatic cancer, toxicity, chitosan-solid lipid nanoparticle, aspirin, curcumin, sulforaphaneThakkar AChenreddy SThio AKhamas WWang JPrabhu SDove Medical PressarticlePancreatic cancertoxicitychitosan-solid lipid nanoparticleaspirincurcuminsulforaphaneMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 3265-3276 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Pancreatic cancer toxicity chitosan-solid lipid nanoparticle aspirin curcumin sulforaphane Medicine (General) R5-920 |
| spellingShingle |
Pancreatic cancer toxicity chitosan-solid lipid nanoparticle aspirin curcumin sulforaphane Medicine (General) R5-920 Thakkar A Chenreddy S Thio A Khamas W Wang J Prabhu S Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| description |
Arvind Thakkar,1 Sushma Chenreddy,1 Astrid Thio,1 Wael Khamas,2 Jeffrey Wang,1 Sunil Prabhu1 1Department of Pharmaceutical Sciences, College of Pharmacy, 2College of Veterinary Medicine, Western University of Health Sciences, Pomona, CA, USA Abstract: Our previous studies have established the efficacy of chemopreventive regimens of aspirin and curcumin (CUR) encapsulated within solid lipid nanoparticles (SLNs) in combination with free sulforaphane (ACS combination) to prevent or delay the initiation and progression of pancreatic cancer, classified as one of the deadliest diseases with very low chances of survival upon diagnosis. Although toxicity of individual drugs and SLN has been studied previously, there are no studies in current literature that evaluate the potential toxicity of a combined regimen of ACS, especially when encapsulated within chitosan-SLNs (c-SLNs). Hence, objective of the current study was to investigate the potential toxic effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), subacute (28 days), and subchronic (90 days) administrations by oral gavage in BALB/c mice. Mice were administered the following regimens: saline, blank c-SLN, low-dose ACS c-SLN (2+4.5+0.16 mg/kg), medium-dose ACS c-SLN (20+45+1.6 mg/kg), and high-dose ACS c-SLN (60+135+4.8 mg/kg). The potential toxicity was evaluated based on animal survival, body weight, hematology, blood chemistry, and organ histopathology. During 3-day, 28-day, and 90-day study periods, no animal deaths were observed. Treatment with ACS c-SLNs did not cause alteration in complete blood counts and blood chemistry data. Histopathological examination of various organ sections (pancreas, heart, liver, kidney, and brain) appeared normal. Based on the results of this study, no signs of toxicity in acute, subacute, and subchronic studies following oral administration of ACS c-SLNs were found indicating that the oral dosing regimens were safe at the levels tested for long-term administration to prevent the onset of pancreatic cancer. Keywords: pancreatic cancer, toxicity, chitosan-solid lipid nanoparticle, aspirin, curcumin, sulforaphane |
| format |
article |
| author |
Thakkar A Chenreddy S Thio A Khamas W Wang J Prabhu S |
| author_facet |
Thakkar A Chenreddy S Thio A Khamas W Wang J Prabhu S |
| author_sort |
Thakkar A |
| title |
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| title_short |
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| title_full |
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| title_fullStr |
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| title_full_unstemmed |
Preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice |
| title_sort |
preclinical systemic toxicity evaluation of chitosan-solid–lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in balb/c mice |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/94ab8fee00204a259e57bfa9e5b78417 |
| work_keys_str_mv |
AT thakkara preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice AT chenreddys preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice AT thioa preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice AT khamasw preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice AT wangj preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice AT prabhus preclinicalsystemictoxicityevaluationofchitosansolidndashlipidnanoparticleencapsulatedaspirinandcurcuminincombinationwithfreesulforaphaneinbalbcmice |
| _version_ |
1718401505931821056 |